A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
This study focuses on people with advanced non-small cell lung cancer. Researchers are exploring various existing and new medications, sometimes in combination, to understand their safety and how well they work. The main goal is to find better treatments for this type of lung cancer. One part of the study, called Sub-study 2, is particularly looking at a drug called rilvegostomig alongside standard chemotherapy, and potentially another drug called ramucirumab. This involves carefully checking for side effects and seeing if the treatments shrink the cancer. The study aims to gather important information to help improve future care for patients.
At a glance
What is this study about?
This research study is designed for individuals who have been diagnosed with advanced non-small cell lung cancer. This is a common type of lung cancer that has either spread to other parts of the body (metastatic) or is considered advanced.
The main aim of this study is to test out different medications, some new and some already used, to see how safe they are and how well they help to shrink or control the cancer. They will be looking at single drugs and also combinations of drugs. One specific part of the study (called Sub-study 2) is focusing on a particular drug called rilvegostomig. This drug will be given alongside standard chemotherapy, and for some, another drug called ramucirumab might be added. By doing this, researchers hope to find new and more effective ways to treat this challenging condition.
This is a 'platform study', which means it's designed to be flexible and test several treatments over time. The results from this study could help doctors understand which treatments work best, guiding future decisions about patient care and potentially offering new hope for people living with non-small cell lung cancer.
Key takeaways
- This study is for advanced non-small cell lung cancer.
- It tests new and existing treatments, often in combination, for safety and effectiveness.
- One specific part focuses on rilvegostomig with chemotherapy.
- Close medical monitoring and regular hospital visits are involved.
- You can withdraw from the study at any time without affecting your care.
Who may be eligible?
To join this study, you must have advanced non-small cell lung cancer that has spread. Doctors will need to confirm your cancer type and check that there's a piece of your tumour tissue available for examination. You also need to have at least one part of your cancer that can be clearly measured by scans.
Your general health also needs to be good enough to take part, meaning your major organs like your kidneys, liver, and blood are working well. You must also be expected to live for at least another 12 weeks. If you are a man or woman, you will need to use accepted birth control methods during the study.
There are also some reasons why you might not be able to join. For example, if your cancer has certain genetic changes that mean other specific treatments are already available. You also can't join if you have certain other serious health problems like uncontrolled high blood pressure, active infections, or other specific types of cancer in the past. If you have autoimmune diseases or certain heart conditions, you also might not be able to participate.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Do you have advanced non-small cell lung cancer that has spread?
- Do you have a biopsy or tissue sample available for review?
- Is your general health good enough, meaning your main organs are working well?
- Are you able to use contraception if required?
- Do you have any other serious health conditions like uncontrolled blood pressure or certain heart problems that might prevent you from joining?
What does participation involve?
If you decide to take part in this study, you will likely have regular hospital visits. During these visits, doctors and nurses will monitor your health closely, perform examinations, take blood and urine samples, and conduct scans to see how the treatment is working. You will receive the study medication as directed by the research team.
One part of the study involves finding the right dose of a new drug, so some participants might receive different doses. After this, more participants will receive the treatment to see how well it works and to continue monitoring safety. The total duration of participaton for each person will likely vary depending on how they respond to the treatment and the specific part of the study they are in, but it will involve ongoing check-ups as long as the treatment is beneficial and safe. There will also be follow-up appointments after the treatment ends to continue monitoring your health.
Potential risks and benefits
Locations (104)
- Research SiteVerified postcodePhoenix, United States· Recruiting
- Research SiteVerified postcodeSanta Rosa, United States· Recruiting
- Research SiteVerified postcodeJacksonville, United States· Recruiting
- Research SiteVerified postcodeBaltimore, United States· Not yet recruiting
- Research SiteVerified postcodeDetroit, United States· Not yet recruiting
- Research SiteVerified postcodeRochester, United States· Recruiting
- Research SiteVerified postcodeCleveland, United States· Recruiting
- Research SiteVerified postcodeProvidence, United States· Recruiting
- Research SiteVerified postcodeProvidence, United States· Withdrawn
- Research SiteVerified postcodeTyler, United States· Recruiting
- Research SiteVerified postcodeAnderlecht, Belgium· Not yet recruiting
- Research SiteVerified postcodeHasselt, Belgium· Not yet recruiting
Common questions
What type of lung cancer does this study focus on?
This study is for advanced non-small cell lung cancer (NSCLC) that has either spread or is considered advanced.
What medicines are being tested?
The study includes several drugs like Rilvegostomig, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, and Ramucirumab, often in combination.
What is the main goal of the study?
The main goal is to check the safety and how well these drugs and drug combinations work in treating advanced lung cancer.
Will I get a new drug or standard treatment?
You might receive a new drug, a standard treatment, or a combination of both, depending on which part of the study you join.
Can I leave the study at any time?
Yes, you can choose to leave the study at any point without it affecting your ongoing medical care.
How to find out more
AstraZeneca Clinical Study Information Center
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.